Results 21 to 30 of about 4,329,929 (348)

Efficient evolution of human antibodies from general protein language models

Nature Biotechnology, 2023
A general protein language model guides protein evolution with 20 or fewer variants needed for testing. Natural evolution must explore a vast landscape of possible sequences for desirable yet rare mutations, suggesting that learning from natural ...
Brian L. Hie, Varun R. Shanker, Duo Xu, Theodora U. J. Bruun, P. Weidenbacher, Shao-Geng Tang, Wesley Wu, J. Pak, Peter S. Kim   +8 more
semanticscholar   +1 more source

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

New England Journal of Medicine, 2020
Coagulopathy in Critical Illness with Covid-19 The authors describe a 69-year-old man with Covid-19 diagnosed in January 2020 in Wuhan, China, along with two other critically ill patients with Covid-19 who were also seen in the same intensive care unit ...
Yan Zhang, M. Xiao, Shu-Lan Zhang, P. Xia, W. Cao, Wei Jiang, Huan Chen, Xin Ding, Hua Zhao, Hong-Min Zhang, Chun-Yao Wang, Jing Zhao, Xue-Feng Sun, R. Tian, Wei Wu, Dong Wu, Jie Ma, Yu Chen, Dong Zhang, Jing Xie, Xiao-Wei Yan, Xiang Zhou, Zheng-Yin Liu, Jing-Lan Wang, B. Du, Yan Qin, Peng Gao, Xu-Zhen Qin, Ying-Chun Xu, Wen Zhang, Tai-Sheng Li, Feng-Chun Zhang, Yong-Qiang Zhao, Yong-Zhe Li, Shu-Yang Zhang   +34 more
semanticscholar   +1 more source

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Nature, 2021
The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising concerns about the effectiveness of available vaccines and antibody-based ...
E. Cameroni, J. Bowen, L. E. Rosen, C. Saliba, S. Zepeda, K. Culap, D. Pinto, Laura A. VanBlargan, A. De Marco, J. di Iulio, F. Zatta, Hannah Kaiser, Julia Noack, Nisar Farhat, N. Czudnochowski, C. Havenar-Daughton, Kaitlin R. Sprouse, J. Dillen, Abigail E. Powell, Alex K Chen, Cyrus Maher, Li Yin, Dan-Dan Sun, Leah B. Soriaga, Jessica Bassi, Chiara Silacci-Fregni, C. Gustafsson, N. Franko, Jennifer K. Logue, N. Iqbal, I. Mazzitelli, J. Geffner, R. Grifantini, Helen Y. Chu, A. Gori, A. Riva, O. Giannini, A. Ceschi, Paolo Ferrari, Pietro E. Cippà, A. Franzetti-Pellanda, C. Garzoni, P. Halfmann, Y. Kawaoka, C. Hebner, L. Purcell, L. Piccoli, M. Pizzuto, A. Walls, M. Diamond, A. Telenti, H. Virgin, A. Lanzavecchia, G. Snell, D. Veesler, D. Corti   +55 more
semanticscholar   +1 more source

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Cell, 2021
The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, the recently emerged SARS-CoV-2 variants B.1.1.7 (UK)
M. Hoffmann, P. Arora, R. Gross, Alina Seidel, Bojan F. Hörnich, Alexander S. Hahn, Nadine Krüger, L. Graichen, Heike Hofmann-Winkler, A. Kempf, M. Winkler, Sebastian R. Schulz, Hans-Martin Jäck, B. Jahrsdörfer, H. Schrezenmeier, Martin Müller, A. Kleger, Jan Münch, S. Pöhlmann   +18 more
semanticscholar   +1 more source

Development of therapeutic antibodies for the treatment of diseases

Journal of Biomedical Sciences, 2020
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved.
Ruei-Min Lu, Yu-Chyi Hwang, I-Ju Liu, Chi-Chiu Lee, Han-zen Tsai, Hsin-Jung Li, Han-Chung Wu   +6 more
semanticscholar   +1 more source

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Science, 2020
An antibody cocktail against SARS-CoV-2 There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al.
A. Baum, Benjamin O. Fulton, Elzbieta Wloga, R. Copin, Kristen E. Pascal, Vincenzo Russo, Stephanie Giordano, Kathryn Lanza, Nicole Negron, M. Ni, Yi Wei, G. Atwal, A. Murphy, N. Stahl, G. Yancopouloš, C. Kyratsous   +15 more
semanticscholar   +1 more source

Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies

bioRxiv, 2022
Prediction of antibody structures is critical for understanding and designing novel therapeutic and diagnostic molecules. Here, the authors present IgFold: a fast, accurate method for antibody structure prediction using an end-to-end deep learning model.
Jeffrey A. Ruffolo, Lee-Shin Chu, S. Mahajan, Jeffrey J. Gray   +3 more
semanticscholar   +1 more source

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

bioRxiv, 2020
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2.
Yiska Weisblum, Fabian Schmidt, Feng-Wen Zhang, Justin DaSilva, D. Poston, Julio C. C. Lorenzi, Frauke Muecksch, Magda Rutkowska, H. Hoffmann, E. Michailidis, C. Gaebler, Marianna Agudelo, Alice Cho, Zi-Jun Wang, A. Gazumyan, M. Cipolla, Larry L. Luchsinger, C. Hillyer, M. Caskey, D. Robbiani, C. Rice, M. Nussenzweig, T. Hatziioannou, P. Bieniasz   +23 more
semanticscholar   +1 more source

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

bioRxiv, 2021
The evolution of SARS-CoV-2 could impair recognition of the virus by human antibody-mediated immunity. To facilitate prospective surveillance for such evolution, we map how convalescent serum antibodies are impacted by all mutations to the spike’s ...
Allison J. Greaney, Andrea N. Loes, Katharine H. D. Crawford, Tyler N. Starr, Keara D. Malone, Helen Y. Chu, J. Bloom   +6 more
semanticscholar   +1 more source

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Science, 2020
Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute ...
T. Rogers, Fang-Zhu Zhao, De-Li Huang, N. Beutler, Alison Burns, Wan-ting He, Oliver Limbo, Chloe Smith, G. Song, J. Woehl, Lin-Lin Yang, R. Abbott, Sean Callaghan, Elijah Garcia, Jonathan Hurtado, M. Parren, Linghang Peng, S. Ramirez, James Ricketts, M. Ricciardi, S. Rawlings, Nicholas C. Wu, M. Yuan, Davey M. Smith, D. Nemazee, J. Teijaro, J. Voss, I. A. Grant Wilson, R. Andrabi, Bryan S. Briney, E. Landais, D. Sok, J. Jardine, D. Burton   +33 more
semanticscholar   +1 more source